Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 24:102:adv00724.
doi: 10.2340/actadv.v102.2048.

Mucocutaneous Adverse Reactions to COVID-19 Vaccines: Do Excipients Play a Role?

Leonardo Bianchi, Filippo Biondi, Katharina Hansel, Nicola Murgia, Alessandro D'Arpino, Marta Tramontana, Luca Stingeni  1
Affiliations

Mucocutaneous Adverse Reactions to COVID-19 Vaccines: Do Excipients Play a Role?

Leonardo Bianchi et al. Acta Derm Venereol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

    1. Pajon R, Doria-Rose NA, Shen X, Schmidt SD, O’Dell S, McDanal C, et al. . SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination. N Engl J Med 2022; 386: 1088–1091. - PMC - PubMed
    1. Greenhawt M, Abrams EM, Shaker M, Chu DK, Khan D, Akin C, et al. . The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach. J Allergy Clin Immunol Pract 2021; 9: 3546–3567. - PMC - PubMed
    1. Català A, Muñoz-Santos C, Galván-Casas C, Roncero Riesco M, Revilla Nebreda D, Solá-Truyols A, et al. . Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol 2022; 186: 142–152. - PMC - PubMed
    1. Sokolowska M, Eiwegger T, Ollert M, Torres MJ, Barber D, Del Giacco S, et al. . EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy 2021; 76: 1629–1639. - PMC - PubMed
    1. Caballero ML, Quirce S. Excipients as potential agents of anaphylaxis in vaccines: analyzing the formulations of currently authorized COVID-19 vaccines. J Investig Allergol Clin Immunol 2021; 31: 92–93. - PubMed